Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 103
mi
from
Phoenix, AZ
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 103
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 108
mi
from
Coronado, CA
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 108
mi
from
Coronado, CA
Click here to add this to my saved trials
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 101
mi
from
Detroit, MI
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 101
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 903
mi
from
Durham, NC
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 903
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 910
mi
from
Dallas, TX
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 910
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 113
mi
from
San Antonia, TX
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 113
mi
from
San Antonia, TX
Click here to add this to my saved trials
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated:  3/27/2017
NGM Clinical Study Site 703
mi
from
Sydney,
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
Status: Enrolling
Updated: 3/27/2017
NGM Clinical Study Site 703
mi
from
Sydney,
Click here to add this to my saved trials
Study of Effects of L-Arginine in Colitis and Colon Cancer
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
Status: Enrolling
Updated:  3/30/2017
Vanderbilt Hospital
mi
from
Nashville, TN
Study of Effects of L-Arginine in Colitis and Colon Cancer
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
Status: Enrolling
Updated: 3/30/2017
Vanderbilt Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Laser Versus Mechanical Lithotripsy of Bile Duct Stones
Randomized Trial of Combination of Cholangioscopic Guided Laser Lithotripsy and Conventional Mechanical Versus Conventional Mechanical Methods for the Endoscopic Removal of Large Bile Duct Stones
Status: Enrolling
Updated:  3/30/2017
Los Angeles County Hospital
mi
from
Los Angeles, CA
Laser Versus Mechanical Lithotripsy of Bile Duct Stones
Randomized Trial of Combination of Cholangioscopic Guided Laser Lithotripsy and Conventional Mechanical Versus Conventional Mechanical Methods for the Endoscopic Removal of Large Bile Duct Stones
Status: Enrolling
Updated: 3/30/2017
Los Angeles County Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Laguna Hills, CA
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Clearwater, FL
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Miami, FL
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Jefferson City, MO
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Jefferson City, MO
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Jackson, TN
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Jackson, TN
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  3/30/2017
Novo Nordisk Investigational Site
mi
from
Sofia,
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 3/30/2017
Novo Nordisk Investigational Site
mi
from
Sofia,
Click here to add this to my saved trials
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy
Status: Enrolling
Updated:  4/3/2017
Pathway Genomics
mi
from
San Diego, CA
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy
Status: Enrolling
Updated: 4/3/2017
Pathway Genomics
mi
from
San Diego, CA
Click here to add this to my saved trials
The Effect Of Vitamin D On Measures Of Bone Health And Gene Expression
The Effect of Vitamin D on Measures of Bone Health and Gene Expression
Status: Enrolling
Updated:  4/3/2017
Boston Med Ctr
mi
from
Boston, MA
The Effect Of Vitamin D On Measures Of Bone Health And Gene Expression
The Effect of Vitamin D on Measures of Bone Health and Gene Expression
Status: Enrolling
Updated: 4/3/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated:  4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated: 4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
University of Alabama
mi
from
Birmingham, AL
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
University of California, San Diego
mi
from
San Diego, CA
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
Northwestern University
mi
from
Chicago, IL
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
University of Michigan
mi
from
Ann Arbor, MI
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
University of Virginia
mi
from
Charlottesville, VA
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated:  4/4/2017
UZ Gasthuisberg
mi
from
Leuven,
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy
Status: Enrolling
Updated: 4/4/2017
UZ Gasthuisberg
mi
from
Leuven,
Click here to add this to my saved trials
Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD
Protective Efficacy of Orally Delivered Bovine Immunoglobulin, Specific for CS17 Fimbriae and CS17 Minor Fimbrial Adhesin CsbD Against Challenge With a CS17 Strain of Enterotoxigenic Escherichia Coli (ETEC)
Status: Enrolling
Updated:  4/4/2017
Center for Immunization Research
mi
from
Baltimore, MD
Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD
Protective Efficacy of Orally Delivered Bovine Immunoglobulin, Specific for CS17 Fimbriae and CS17 Minor Fimbrial Adhesin CsbD Against Challenge With a CS17 Strain of Enterotoxigenic Escherichia Coli (ETEC)
Status: Enrolling
Updated: 4/4/2017
Center for Immunization Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD
Protective Efficacy of Orally Delivered Bovine Immunoglobulin, Specific for CS17 Fimbriae and CS17 Minor Fimbrial Adhesin CsbD Against Challenge With a CS17 Strain of Enterotoxigenic Escherichia Coli (ETEC)
Status: Enrolling
Updated:  4/4/2017
Johns Hopkins Bayview Medicial Center, Inpatient Unit
mi
from
Baltimore, MD
Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD
Protective Efficacy of Orally Delivered Bovine Immunoglobulin, Specific for CS17 Fimbriae and CS17 Minor Fimbrial Adhesin CsbD Against Challenge With a CS17 Strain of Enterotoxigenic Escherichia Coli (ETEC)
Status: Enrolling
Updated: 4/4/2017
Johns Hopkins Bayview Medicial Center, Inpatient Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
Status: Enrolling
Updated:  4/4/2017
UCSD Medical Center
mi
from
San Diego, CA
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
Status: Enrolling
Updated: 4/4/2017
UCSD Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
Status: Enrolling
Updated:  4/4/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
Status: Enrolling
Updated: 4/4/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
Status: Enrolling
Updated:  4/4/2017
Newbridge Medical Research Corp., Warren General Hosp.
mi
from
Warren, PA
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
Status: Enrolling
Updated: 4/4/2017
Newbridge Medical Research Corp., Warren General Hosp.
mi
from
Warren, PA
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Birmingham, AL
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Mesa, AZ
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Tucson, AZ
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Jonesboro, AR
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Bakersfield, CA
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Fresno, CA
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Hialeah, FL
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Miami, FL
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
North Miami Beach, FL
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
South Miami, FL
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Lexington, KY
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Baltimore, MD
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Cambridge, MA
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Cambridge, MA
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Missoula, MT
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated:  4/10/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Status: Enrolling
Updated: 4/10/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials